Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study
Main finding · MortalityResult — go to the resultHazard ratio 0.60 95% CI 0.43–0.84Authors' conclusion
In patients with diabetes and STEMI, GLP-1RA treatment prior to STEMI admission was associated with significantly lower long-term mortality.
Study context
- Population
- Consecutive patients admitted with T2D and STEMI in Denmark, 2010–2016; 7% treated with GLP-1 RA before STEMI, 93% not
- Participants
- 1,421 patients
- Exposure
- GLP-1 RA treatment before STEMI vs no GLP-1 RA
- Outcome
- Long-term mortality
- Follow-up
- 8.4 years
Methodological detailsregistry-based, consecutive patients, All data retrieved from nationwide Danish registries
- Registry-based
- Consecutive patients
- All data retrieved from nationwide Danish registries
Main finding
Mortality
Hazard ratio
0.60
95% CI 0.43–0.84
By group
GLP-1RAvs No GLP-1RA
HR 0.60 (95% CI 0.43–0.84)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| Ischaemic strokeNo association | 1.05 (0.57–1.94) | |
| Recurrent MINo association | 0.74 (0.48–1.15) | |
| Hospitalisation for HFNo association | 0.71 (0.48–1.05) | |
| 0.512Adjusted hazard ratio (log scale) |
Original publication
Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol. Published 4 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →